Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Rene Nunez"'
Publikováno v:
Frontiers in Psychiatry, Vol 13 (2022)
BackgroundPimavanserin prolongs the QT interval, with mean increases in corrected QT (QTc) of 5–8 ms, and is currently being investigated for the treatment of negative symptoms of schizophrenia.ObjectivesTo assess QT interval prolongation in 3 stud
Externí odkaz:
https://doaj.org/article/34afd38db4714a0ea5843e4cda309bc6
Publikováno v:
Estudios de Asia y Africa, 2013 May 01. 482(151), 357-380.
Externí odkaz:
https://www.jstor.org/stable/23608203
Publikováno v:
Ecología Política, 2004 Jan 01(28), 91-102.
Externí odkaz:
https://www.jstor.org/stable/20743572
Autor:
Marcelo López-Ramírez, Ignacio Espinoza, Felipe Sierra, Bastián Grass, René Núñez, Gonzalo Miranda
Publikováno v:
Revista Chilena de Radiología, Vol 30, Iss 3 (2024)
La articulación temporomandibular (ATM) es una articulación sinovial móvil que articula el hueso temporal, particularmente el tubérculo articular y la fosa glenoidea, con el cóndilo del hueso mandibular. En su interior existe un disco articular
Externí odkaz:
https://doaj.org/article/c1b611f7ba354b688aa91999fea21940
Autor:
Victor Abler, Marc Cantillon, Jason L. Aldred, Lori Jacobi, Gustavo Alva, James C. Norton, Daryl DeKarske, Rene Nunez, Bruce Coate
Publikováno v:
Journal of Parkinson's Disease
Background: Many patients with Parkinson’s disease (PD) experience depression. Objective: Evaluate pimavanserin treatment for depression in patients with PD. Methods: Pimavanserin was administered as monotherapy or adjunctive therapy to a selective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bde8bb7f1da2492cfaadc2f244aabb1
https://pubmed.ncbi.nlm.nih.gov/32804101
https://pubmed.ncbi.nlm.nih.gov/32804101
Autor:
Suresh Durgam, David V. Sheehan, Giovanna Forero, Xiongwen Tang, Rene Nunez, Carl Gommoll, Maju Mathews
Publikováno v:
The Journal of Clinical Psychiatry. 77:1687-1694
Objective To evaluate the efficacy, safety, and tolerability of vilazodone as an acute treatment for generalized anxiety disorder (GAD). Vilazodone is a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist approved for the treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01080a10db9f96c741506d0a8fdb801a
https://doi.org/10.4088/jcp.15m09885
https://doi.org/10.4088/jcp.15m09885
Autor:
Rene Nunez, Mohammed A Bari, Ramzey Odetalla, Peter D Feldman, Dragana Bugarski-Kirola, I-Yuan Liu, Srdjan Stankovic, István Bitter
Publikováno v:
Schizophrenia Bulletin
Background Many patients with schizophrenia (SCZ) do not fully respond to antipsychotic (AP) treatment despite adherence and require augmentation, often with an AP with similar mode of action. Evidence supporting polypharmacy is limited and adding an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3972f5139a4d6f7054a7c1c8fc97b76
http://europepmc.org/articles/PMC7234223
http://europepmc.org/articles/PMC7234223
Autor:
Angelo Sambunaris, Suresh Durgam, Xiongwen Tang, Giovanna Forero, Carl Gommoll, Maju Mathews, Rene Nunez
Publikováno v:
International Clinical Psychopharmacology
Vilazodone is a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist that is approved for treatment of major depressive disorder in adults in the USA and Mexico. The efficacy, safety, and tolerability of vilazodone for general
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d4d8790211580585dd46be80230442f
https://doi.org/10.1097/yic.0000000000000096
https://doi.org/10.1097/yic.0000000000000096
Publikováno v:
International Clinical Psychopharmacology
Sexual dysfunction commonly occurs with major depressive disorder (MDD). Vilazodone, a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist antidepressant approved for the treatment of MDD in adults, was evaluated to determine i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2201759a73bfb1524dff77087e617557
https://doi.org/10.1097/yic.0000000000000075
https://doi.org/10.1097/yic.0000000000000075
Autor:
Suresh Durgam, Michael E. Thase, Maju Mathews, Xiongwen Tang, Carl Gommoll, Rene Nunez, Giovanna Forero
Publikováno v:
Depression and Anxiety
Background Vilazodone, a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist, is approved for treating major depressive disorder in adults. This study (NCT01629966 ClinicalTrials.gov) evaluated the efficacy and safety of vilazo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bbe5effb678a947dbb92ef6ba06edce
https://doi.org/10.1002/da.22365
https://doi.org/10.1002/da.22365